Chronic Heart Failure

Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction

The EMPEROR-Preserved trial evaluated the efficacy of empagliflozin, an SGLT2 inhibitor, in patients with chronic heart failure with preserved ejection fraction (HFpEF). This international, multicenter study included 5,998 participants and was conducted across 622 centers in 23 countries. Patients were randomized to receive either empagliflozin (10 mg daily) or a placebo, alongside standard care, over a median follow-up period of 26 months.

Key findings from the trial include a 21% reduction in the combined risk of cardiovascular death or hospitalization for heart failure among those treated with empagliflozin compared to placebo. The reduction in total heart failure hospitalizations was even more pronounced at 27%. These benefits were observed regardless of the presence of diabetes. Empagliflozin also slowed the decline in renal function compared to the placebo group, further highlighting its potential therapeutic advantages in HFpEF management​

    Related Conference of Chronic Heart Failure

    December 12-13, 2024

    13th World Heart Congress

    Rome, Italy
    December 12-13, 2024

    5th Global Summit on Heart Congress

    Dubai, UAE
    December 26-27, 2024

    28th World Cardiology Conference

    Paris, France
    February 20-21, 2025

    35th International Conference on Cardiology and Healthcare

    Amsterdam, Netherlands
    February 20-21, 2025

    14th World Congress on Cardiology

    Amsterdam, Netherlands
    February 24-25, 2025

    40th World Cardiology Conference

    London, UK
    February 27-28, 2025

    4th Global Summit on Cardiology and Cardiac Surgery

    Paris, France
    March 24-25, 2025

    14th World Heart Congress

    Paris, France
    April 16-17, 2025

    8th World Heart and Brain Conference

    Tokyo, Japan
    April 24-25, 2025

    9th Annual Heart Rhythm Conference

    Vienna, Austria
    April 28-29, 2025

    37th World Congress on Cardiology & Heart Diseases

    Frankfurt, Germany
    April 28-29, 2025

    39th World Congress on Heart Diseases

    Frankfurt, Germany
    May 19-20, 2025

    4th International Conference on Cardiology

    Rome, Italy
    May 22-23, 2025

    5th World Congress on Congestive Heart Failure & Angina

    Zurich, Switzerland
    May 26-27, 2025

    6th European Summit on Cardiology Research

    Rome, Italy
    August 11-12, 2025

    3rd International Conference on World Heart Care

    Toronto, Canada
    August 21-22, 2025

    8th Global Cardiovascular Research and Clinical Cardiology

    Vancouver, Canada
    September 08-09, 2025

    39th European Cardiology Conference

    Frankfurt, Germany

    Chronic Heart Failure Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in